1-3 of 3
Mylissa Borek
Close
Sort by
Journal Articles

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Robert N Booher, PhD, Grzegorz S. Nowakowski, MD, Krish Patel, MD, Matthew A. Lunning, DO, Maria Elena S. Samson, B.S., Ruzanna Atoyan, MD, Anna W Ma, MS, Guang-Xin Xu, BS, Steven Dellarocca, B.S., Holly Modafferi, BS, Mylissa Borek, B.S., Zhidong Zhang, PhD, Jefferson Parker, PhD, Duncan Whitney, PhD, Hongwei Wang, MD, David P Tuck, MD, Anas Younes, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4168.
https://doi.org/10.1182/blood-2018-99-117383
Published: 2018
Journal Articles

Combination of IRAK4 Inhibitor CA-4948 with BCL2 Inhibitor Venetoclax Induces Tumor Regression in an ABC-DLBCL Xenograft Model

Robert Booher, PhD, Steven Dellarocca, B.S., Ruzanna Atoyan, MD, Mylissa Borek, B.S., Maria Elena S. Samson, B.S., David Tuck, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1534.
https://doi.org/10.1182/blood.V130.Suppl_1.1534.1534
Published: 2017
Journal Articles

CUDC-907, a Dual HDAC and PI3K Inhibitor, Potentially Targets Cancer Cells and The Microenvironment In Hematological Malignancies

Jing Wang, PhD, Natalie Pursell, PhD, Anna Ma, Ruzanna Atoyan, Maria Samson, Mylissa Borek, Steven DellaRocca, Ling Yin, Da-gong Wang, Brian Zifcak, Guang-xin Xu, Maurizio Voi, MD, Cheng-Jung Lai, PhD
Journal: Blood
Blood (2013) 122 (21): 4930.
https://doi.org/10.1182/blood.V122.21.4930.4930
Published: 2013